Literature DB >> 3200183

Changing antibiotic prescribing by educational marketing.

F T Landgren1, K J Harvey, M L Mashford, R F Moulds, B Guthrie, M Hemming.   

Abstract

A controlled cross-over study in 12 Victorian public hospitals was performed to examine the power of marketing techniques in influencing prescribing. The targeted prescribing behaviour was the use of antibiotic prophylaxis in surgery, and the criteria for judging the appropriateness of therapy were its duration and timing, as are detailed in the fourth edition of the booklet Antibiotic guidelines. The first intervention was mounted in 1985 in six hospitals (two metropolitan teaching hospitals, one suburban general hospital and three rural hospitals), and six matched hospitals acted as control hospitals. One year later, the intervention was mounted in the six hospitals that previously had been the control hospitals. The interventional campaign consisted of material that was similar to that which is used by the pharmaceutical industry, including an "academic" representative. Its effect was assessed by audits that were performed before and after the first interventional campaign and again, one year later, after the second interventional campaign. The proportion of antibiotic courses that were assessed as satisfactory in terms of duration increased significantly after the first campaign in the hospitals where the intervention was mounted. No significant changes in prescribing occurred in the control hospitals. In the hospitals which were control hospitals in 1985, and in which the intervention occurred in 1986, the proportion of antibiotic courses that were assessed as satisfactory also increased significantly after the interventional campaign. A fall-off in performance occurred during the 12 months after the campaign in the 1985-interventional hospitals. Calculated cost savings more than outweighed the costs of the campaign. We conclude that inappropriate prescribing behaviour in hospitals can be modified successfully by educational marketing techniques.

Mesh:

Substances:

Year:  1988        PMID: 3200183     DOI: 10.5694/j.1326-5377.1988.tb120797.x

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  20 in total

1.  Changing doctor prescribing behaviour.

Authors:  P S Gill; M Mäkelä; K M Vermeulen; N Freemantle; G Ryan; C Bond; T Thorsen; F M Haaijer-Ruskamp
Journal:  Pharm World Sci       Date:  1999-08

Review 2.  Pharmacoeconomic consequences of measurement and modification of hospital drug use.

Authors:  L L Ioannides-Demos; G M Eckert; A J McLean
Journal:  Pharmacoeconomics       Date:  1992-07       Impact factor: 4.981

Review 3.  Pharmacoeconomics of antibacterial treatment.

Authors:  P G Davey; M M Malek; S E Parker
Journal:  Pharmacoeconomics       Date:  1992-06       Impact factor: 4.981

Review 4.  Impact of drug usage review on drug utilisation.

Authors:  J L Blackburn
Journal:  Pharmacoeconomics       Date:  1993-01       Impact factor: 4.981

Review 5.  Developing and implementing clinical practice guidelines.

Authors:  J Grimshaw; N Freemantle; S Wallace; I Russell; B Hurwitz; I Watt; A Long; T Sheldon
Journal:  Qual Health Care       Date:  1995-03

6.  The Nelson Prescribing Project. A programmed intervention in general practice in New Zealand.

Authors:  R I Ferguson; C E Salmond; T J Maling
Journal:  Pharmacoeconomics       Date:  1995-06       Impact factor: 4.981

Review 7.  Achieving health gain through clinical guidelines II: Ensuring guidelines change medical practice.

Authors:  J M Grimshaw; I T Russell
Journal:  Qual Health Care       Date:  1994-03

8.  Killing me softly: myth in pharmaceutical advertising.

Authors:  Tim Scott; Neil Stanford; David R Thompson
Journal:  BMJ       Date:  2004-12-18

9.  Antibiotics policies in the developing world.

Authors:  A J Smith; J K Aronson; M Thomas
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

10.  Defining criteria for the pharmacoeconomic evaluation of new oral cephalosporins.

Authors:  P G Davey; M Malek
Journal:  Pharmacoeconomics       Date:  1994       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.